0001493152-17-005975.txt : 20170530 0001493152-17-005975.hdr.sgml : 20170530 20170530161035 ACCESSION NUMBER: 0001493152-17-005975 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 30 CONFORMED PERIOD OF REPORT: 20170530 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20170530 DATE AS OF CHANGE: 20170530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PetLife Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001354591 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] IRS NUMBER: 331133537 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52445 FILM NUMBER: 17877510 BUSINESS ADDRESS: STREET 1: 38 WEST MAIN STREET CITY: HANCOCK STATE: MD ZIP: 21750 BUSINESS PHONE: 844-473-8543 MAIL ADDRESS: STREET 1: 38 WEST MAIN STREET CITY: HANCOCK STATE: MD ZIP: 21750 FORMER COMPANY: FORMER CONFORMED NAME: ECO VENTURES GROUP, INC. DATE OF NAME CHANGE: 20110602 FORMER COMPANY: FORMER CONFORMED NAME: Modern Renewable Technologies, Inc. DATE OF NAME CHANGE: 20100114 FORMER COMPANY: FORMER CONFORMED NAME: Vault Technology, Inc. DATE OF NAME CHANGE: 20080507 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): May 30, 2017

PetLife Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Nevada

000-52445

33-1133537

(State or other jurisdiction

of incorporation)

(Commission
File Number)

(I.R.S. Employer

Identification No.)

38 West Main St., Hancock, MD		21750
(Address of Principal Executive Offices)		(Zip Code)

Registrant's telephone number, including area code: (844) 473-8543

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On May 27, 2017, PetLife Pharmaceuticals, Inc. (“PetLife”) released a press release titled “PetLife Management Comments on Recent Market Activity,” which stated certain current evaluations by PetLife management on the PetLife’s press releases and other activity (“Press Release 5/27/17.” see Exhibit 99.1).

As stated within Press Release 5/27/17, PetLife has issued several other press releases since August 25, 2016. After Press Release 5/27/17, PetLife issued a press release at 6AM EDT on May 30, 2017, titled “PetLife Files for Patent for the Treatment of Cancer for Pets” (see Exhibit 99.2). The press releases from May 27, 2017 back to August 25, 2016, as reflected in descending order, are as stated below:

May 26, 2017	PetLife Explores New Scorpion Venom-Based Therapies for Growing Product Line	Press Release

May 23, 2017	PetLife Closes Acquisition of Assets for Dr. Geoff's Real Food for Pets	Press Release

May 16, 2017	PetLife Pharmaceuticals Engages Carter, Terry & Company for Financing of FDA Application	Press Release

Apr 18, 2017	PetLife Finalizes Negotiations for Dr. Geoff’s Real Food for Pets	Press Release

Apr 12, 2017	PetLife: Holistic Pet Health is Next Big Trend in Veterinary Medicine	Press Release

Mar 24, 2017	PetLife: Millennial Pet Owners Leading Charge in Rapid Growth of Holistic Pet Care	Press Release

Mar 21, 2017	PetLife Supersedes Expectations for the Acquisition of Dr. Geoff’s Real Food for Pets	Press Release

Mar 7, 2017	PetLife Pharmaceuticals Provides an Eye-Opening View on a Recession Resistive Industry	Press Release

Feb 28, 2017	PetLife Pharmaceuticals Signs Letter of Intent to Acquire Healthy Life Pets Brand	Press Release

Feb 21, 2017	PetLife Pharmaceutical Taps National Public Relations Firm to Help Bring to Market Cancer Treatment Originally Developed by Cuba	Press Release

Feb 9, 2017	World Renowned Veterinary Nutritionist Dr. R. Geoffrey Broderick Continues Groundbreaking Efforts to Help Animals by Joining PetLife Pharmaceuticals, Inc. as the Chairman of Product Development and Advisory Board	Press Release

Feb 3, 2017	PetLife Pharmaceuticals Announces Son of World Famous Veterinarian & Pet Industry Innovator, Geoffrey Broderick, to Join the Company as the New President	Press Release

Jan 10, 2017	PetLife Pharmaceuticals reports the First of Three Preclinical Studies in their pre-INAD Process for Vitalzul. Blue Scorpion Venom Toxicity Study Results Show No Adverse Reactions across Multiple Dosing Levels.	Press Release

Dec 7, 2016	Correction: PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line	Press Release

Dec 7, 2016	PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line	Press Release

Dec 6, 2016	PetLife Pharmaceuticals’ CEO Dr. Salvagno Provides White Paper on “Venenotherapy” While Preparing for FDA Submission	Press Release

Dec 1, 2016	PetLife Pharmaceuticals Updates Shareholders on the Company Progress with Vitalzul™ Studies and Additional Product Offerings	Press Release

Nov 15, 2016	PetLife Pharmaceuticals Notes Recent Cuban Research Providing Profound Evidence of Caribbean Blue Scorpion Venom's Ability to Eradicate Cancer Cells as Continued Support for PetLife's pre- INAD Studies of Vitalzul™	Press Release

Oct 27, 2016	PetLife Pharmaceuticals and Lumleian, LLC Announce Partnership to Advance Development and Commercialization of Promising Veterinary Health Pipeline	Press Release

Oct 24, 2016	PetLife Pharmaceuticals Announces the Addition of a Seasoned Marketing Specialist and Investor, Mrs. Vyvyan Campbell, to the Board of Directors	Press Release

Oct 20, 2016	PetLife Pharmaceuticals Announces the Addition of Dr. Simon Wood PhD as the Company’s new Scientific Officer with plans to expand its Current Portfolio of Veterinarian Drugs and Nutraceuticals	Press Release

Oct 17, 2016	PetLife Pharmaceuticals is Pleased to Announce the Completion of the New Company Website	Press Release

Oct 13, 2016	PetLife Pharmaceuticals Expands Cell Line Study with InnoVision in Preparation for FDA/CVM Registration Submission	Press Release

Oct 10, 2016	PetLife Pharmaceuticals is Pleased to Showcase its New “Vitalzul™ Information Video” along with a Corporate Update	Press Release

Sep 7, 2016	PetLife Pharmaceuticals Announces pre-INAD (Investigational New Animal Drug) Cell Lines Study of Vitalzul™ has Begun	Press Release

Sep 1, 2016	PetLife Pharmaceuticals Sees Vitalzul™ as a Major Component in the Treatment of Cancer in Pets; Releases Vitalzul™ Information and Testimonial Video	Press Release

Aug 25, 2016	PetLife Pharmaceuticals Hires InnoVision Therapeutics in Preparation of Vitalzul™ FDA Submission	Press Release

As reflected in the 27 press releases issued by PetLife since August 25, 2016 through May 26. 2017, which does not include Press Release 5/27/17, over the 9-month period, PetLife has averaged 3 press releases per month, with an actual breakdown, by month, as follows: May 2017, 3; April 2017, 2; March 2017, 3; February 2017, 4; January 2017, 1; December 2016, 4; November 2016, 1; October 2016, 6; September 2016, 2; and August 2016, 1. The 27 press releases are seen in Exhibits 99.3 through 99.29.

The press releases reflect the growth of PetLife, specifically in its flagship product, Vitalzul™. The development of Vitalzul™, as reflected over time shows the path to application to the United States Food and Drug Administration (“FDA”) and noted intellectual properties.

PetLife has, from time-to-time, contracted with third-party firms that specialize in investor and public relations. PetLife has used the following firms, as reflected below, during the stated periods.

Gregory FCA	February 20, 2017 to April 20, 2017
Invicto Group	July 8, 2016 to October 8, 2016
Worldwide Holdings dba Invictus Resources	September 1, 2016 to November 30, 2016

PetLife, since January 1, 2016, has not had any conversions from debt instruments into securities of PetLife.

Item 9.01 Financial Statements and Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this report:

Exhibit No.		Description

99.1		Press Release titled “PetLife Management Comments on Recent Market Activity” as released on May 28, 2017

99.2		Press Release titled “PetLife Files for Patent for the Treatment of Cancer for Pets” as released on May 30, 2017

99.3		Press Release titled “PetLife Explores New Scorpion Venom-Based Therapies for Growing Product Line” as released on May 26, 2017

99.4		Press Release titled “PetLife Closes Acquisition of Assets for Dr. Geoff’s Real Food for Pets” as released on May 23, 2017

99.5		Press Release titled “PetLife Pharmaceuticals Engages Carter, Terry & Company for Financing of FDA Application” as released on May 16, 2017

99.6		Press Release titled “PetLife Finalizes Negotiations for Dr. Geoff’s Real Food for Pets” as released on April 18, 2017

99.7		Press Release titled “PetLife: Holistic Pet Health is Next Big Trend in Veterinary Medicine” as released on April 12, 2017

99.8		Press Release titled “PetLife: Millennial Pet Owners Leading Charge in Rapid Growth of Holistic Pet Care” as released on March 24, 2017

99.9		Press Release titled “PetLife Supersedes Expectations for the Acquisition of Dr. Geoff’s Real Food for Pets” as released on March 21, 2017

99.10		Press Release titled “PetLife Pharmaceuticals Provides an Eye-Opening View on a Recession Resistive Industry” as released on March 7, 2017

99.11		Press Release titled “PetLife Pharmaceuticals Signs Letter of Intent to Acquire Healthy Life Pets Brand” as released on February 28, 2017

99.12		Press Release titled “PetLife Pharmaceutical Taps National Public Relations Firm to Help Bring to Market Cancer Treatment Originally Developed by Cuba” as released on February 21, 2017

99.13		Press Release titled “World Renowned Veterinary Nutritionist Dr. R. Geoffrey Broderick Continues Groundbreaking Efforts to Help Animals by Joining PetLife Pharmaceuticals, Inc. as the Chairman of Product Development and Advisory Board” as released on February 9, 2017

99.14		Press Release titled “PetLife Pharmaceuticals Announces Son of World Famous Veterinarian & Pet Industry Innovator, Geoffrey Broderick, to Join the Company as the New President” as released on February 3, 2017

99.15		Press Release titled “PetLife Pharmaceuticals reports the First of Three Preclinical Studies in their pre-INAD Process for Vitalzul. Blue Scorpion Venom Toxicity Study Results Show No Adverse Reactions across Multiple Dosing Levels” as released on January 10, 2017

99.16		Press Release titled “Correction: PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line” as released on December 7, 2016

99.17		Press Release titled “PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line” as released on December 7, 2016

99.18		Press Release titled “PetLife Pharmaceuticals’ CEO Dr. Salvagno Provides White Paper on “Venenotherapy” While Preparing for FDA Submission” as released on December 6, 2016

99.19		Press Release titled “PetLife Pharmaceuticals Updates Shareholders on the Company Progress with Vitalzul™ Studies and Additional Product Offerings” as released on December 1, 2016

99.20		Press Release titled “PetLife Pharmaceuticals Notes Recent Cuban Research Providing Profound Evidence of Caribbean Blue Scorpion Venom’s Ability to Eradicate Cancer Cells as Continued Support for PetLife’s pre-INAD Studies of Vitalzul™” as released on November 15, 2016

99.21		Press Release titled “PetLife Pharmaceuticals and Lumleian, LLC Announce Partnership to Advance Development and Commercialization of Promising Veterinary Health Pipeline” as released on October 27, 2016

99.22		Press Release titled “PetLife Pharmaceuticals Announces the Addition of a Seasoned Marketing Specialist and Investor, Mrs. Vyvyan Campbell, to the Board of Directors” as released on October 24, 2016

99.23		Press Release titled “PetLife Pharmaceuticals Announces the Addition of Dr. Simon Wood PhD as the Company’s new Scientific Officer with plans to expand its Current Portfolio of Veterinarian Drugs and Nutraceuticals” as released on October 20, 2016

99.24		Press Release titled “PetLife Pharmaceuticals is Pleased to Announce the Completion of the New Company Website” as released on October 17, 2016

99.25		Press Release titled “PetLife Pharmaceuticals Expands Cell Line Study with InnoVision in Preparation for FDA/CVM Registration Submission” as released on October 13, 2016

99.26		Press Release titled “PetLife Pharmaceuticals is Pleased to Showcase its New “Vitalzul™ Information Video” along with a Corporate Update as released on October 10, 2016

99.27		Press Release titled “PetLife Pharmaceuticals Announces pre-INAD (Investigational New Animal Drug) Cell Lines Study of Vitalzul™ has Begun” as released on September 7, 2016

99.28		Press Release titled “PetLife Pharmaceuticals Sees Vitalzul™ as a Major Component in the Treatment of Cancer in Pets; Releases Vitalzul™ Information and Testimonial Video” as released September 1, 2016

99.29		Press Release titled “PetLife Pharmaceuticals Hires InnoVision Therapeutics in Preparation of Vitalzul™ FDA Submission” as released on August 25, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PETLIFE PHARMACEUTICALS, INC.

(Registrant)

Dated: May 30, 2017	By:	/s/ Ralph T. Salvagno, MD
		Ralph T. Salvagno, MD
		Chief Executive Officer

EX-99.1 2 ex99-1.htm

PetLife Management Comments on Recent Market Activity

HANCOCK, MD / ACCESSWIRE / May 28, 2017 /PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the “Company,” “We”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced the Company’s comments on recent developments in its stock price and trading performance.

The Company is confident that the main reason of the investors’ interest in its stock is our business performance, which is reflected on the Company’s website and its press releases (http://www.petlifepharma.com/investor-relations/), as well as has been presented to numerous investors during road shows conducted by the Company in several cities. We have been pleased to announce a string of positive developments with our business, which we believe to have been the procuring cause of investors’ buying our stock at or about the times when the Company announced such good business-related news or has investor presentations. At the same time, we became aware of the efforts to promote our stock by various penny stock-touting websites, newsletter publishers and IR marketing services, unknown to and unaffiliated with the Company. We first noticed that activity in February 2017, and observed the same type of efforts recently.

It is our understanding that such promotional activities happen when companies quoted on OTC Markets publish news, which cause the prices of their respective stocks to move. Third party stock promoters scan the market, mention stocks, which they find on the move, to their subscribers, claim credit for such moves, and solicit payments from both subscribers and others.

We do not believe that such promotional activities unauthorized, unrelated to, and not approved by the Company, can cause a significant number of investors to buy our stock. We strongly believe that the main reasons for the investors buying the stock of our Company have been our business performance reflected in press releases and presented to multiple accredited investors during our road shows. Unfortunately, the activities of third party stock promoters seeking to exploit positive developments in our business and appreciation of our stock price have a clear adverse effect on our stock price as follows. Apparently, market makers engaged in predatory short selling are among the most active subscribers to the services of such stock promoters. For example, our stock price moved up recently as the result of the positive press release published on May 23, 2017. That was picked up and exploited by some stock-touting websites and already on May 25, 2017 (according to FINRA’s web page tracking the short-selling at http://regsho.finra.org/FORFshvol20170525.txt), 226,257 shares of our stock were sold short in one day. That is 60% of the daily volume of trading on that date. We have also observed what appears to be a very active short-selling activity on May 26, 2017, when another positive press release caused our stock price to move up. The Company may be addressing this with the market regulators, including naming the most active short-selling market makers, in a hope that both OTC Marketplace and FINRA interfere with their predatory market price manipulations.

It is our obligation to OTC Marketplace and the investors to hereby state that after inquiry of the Management of the Company, we have determined that the directors, control persons, its officers, directors, or any controlling shareholders (defined as shareholders owning 10% or more of the Company’s securities) have not, directly, or indirectly, been involved in any way (including payment of a third-party), with the creation or distribution of promotional materials related to the Company and its securities. Furthermore, after inquiry of management, we have determined that the directors and control persons, the Company, its officers, directors or any controlling shareholders have sold or purchased the Company’s securities within the past 90 days.

In order to further address the concerns related to the unauthorized promotional activities the Company will be putting out a SEC Form 8-K enumerating all the relevant press releases as well as naming the list of third party providers engaged by the Company to provide investor relations services, public relations services, marketing, or other related services, including the promotion of the Company or its securities, since January 1, 2016. We are also planning to address in the same SEC Form 8-K filing, the detailed information about shares or convertible instruments issued by the Company allowing conversion to equity securities at prices constituting a discount to the current market rate at the time of the issuance.

Furthermore, the Company needs to draw attention of some materially inaccurate and outdated information, which has been included in the unauthorized and unapproved disseminations. In particular, the mentioning of “Gain” of 349% relating to a historical stock price is materially incorrect as it fails to account for a 5:1 reverse merger that occurred during the interval in question. Additionally, as part of our negotiations with our former CEO, we have removed all mentions of Escozine from the approved Company literature, including any claims made by the manufacturer of Escozine. The Company abandoned the use of the term “organic” in its authorized publications. The use of the term “Escozine for Pets” was abandoned by the Company in favor of VitalzulTM. The Company does not currently describe its products as “a preventative and treatment for cancer.” Additionally, the Company has no opinion on the accuracy of any technical analysis represented in some unauthorized disseminations. No technical analysis has been performed by the Company regarding its stock.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife’s mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company’s first product, VitalZul™, is currently in testing. VitalZul’s™ active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications. PetLife’s acquired brand, Dr. Geoff’s Real Food for Pets, will incorporate VitalZul™ in its pet food line in 2018.

Forward looking statement:

This press release contains certain “forward-looking statements,” as defined in the United States PSLR Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. The economic, competitive, governmental, technological and other factors identified in the Company’s previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Contact:

Clifford Price

Clifford@PetLifePharma.com

844-473-8543 ext. 701

SOURCE: PetLife Pharmaceuticals, Inc.

EX-99.2 3 ex99-2.htm

PetLife Files for Patent for the Treatment of Cancer for Pets

Combining Chlorotoxin and Plant-based Therapeutic for VitalZul™ for Dogs and Cats

HANCOCK, MD / ACCESSWIRE / May 30, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that they have filed for patent protection in India and the United States for the formula for VitalZul™.

The Company, through an officer of the Company, has filed for a patent in India titled, A Composition for Targeting Cancer in Canines and Humans. The patent protection is for both process and composition thus protecting not only the physical elements of our formulation but also the process by which they are combined. The patent formulation is intended for both animal and human use, pending further testing.

The filing in the United States was titled the same as the India patent with the same attributes as filed in India.

The elements of the formulation of VitalZul™ have been shown to have extremely minimal toxicity. The components of the formulation are natural, not synthetic.

Dr. Ralph Salvagno, CEO of PetLife, stated, “Our team of scientists and researchers in India and in the U.S. have worked diligently to bring VitalZul™ to the next stage of our growth plan. With the patents filed, we will continue the course towards our FDA application. The goal is to bring VitalZul™ to market by the end of 2018.”

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife’s mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology, with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company’s first product, VitalZul™, is currently in testing. VitalZul’s™ active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015, with over $29 billion spent on veterinary care and medications. PetLife’s acquired brand, Dr. Geoff’s Real Food for Pets, will incorporate VitalZul™ in its pet food line in 2018.

Forward-Looking Statement:

Press Contact

Clifford Price

Clifford@PetLifePharma.com

844-473-8543 ext. 701

SOURCE: PetLife Pharmaceuticals, Inc.

EX-99.3 4 ex99-3.htm

PetLife Explores New Scorpion Venom-Based Therapies for Growing Product Line

May 26, 2017

OTC Disclosure & News Service

HANCOCK, MD / ACCESSWIRE / May 26, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that they are exploring various new products for their product line.

PetLife research has verified that scorpion venoms may also have antibacterial and anti-inflammatory properties. The action of most venoms may be due to the primary toxin but, also is likely influenced by other components in the venom. These components, even in small quantities, may hold the key to the true action of scorpion venom. The advantages of using natural venom, as opposed to synthetic venom, is that all components of the venom are included in the therapeutic formulation. The effect of certain venoms as anti-tumor agents has been cited in the literature. Aside from the known anti-tumorigenic action of the primary toxin, other components of the venom may explain the venom’s action on other disease state cells. The PetLife research team is evaluating the potential for scorpion venom-based therapy for common companion pet diseases, such as Lyme disease and arthritis.

Dr. Ralph Salvagno, CEO of PetLife, stated, “Traditionally, research in scorpion venom therapy has centered around the treatment of ‘envenomation,’ which is the scientific name for scorpion stings. Our research team recognizes the potential benefit of scorpion venom for the treatment of significant medical conditions that affect our pets and will continue with their research in this field. We hope to be able to add non-toxic natural-based treatment for several diseases to our portfolio in the future.”

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife’s mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company’s first product, VitalZul™, is currently in testing. VitalZul’s™ active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015, with over $29 billion spent on veterinary care and medications. PetLife’s acquired brand, Dr. Geoff’s Real Food for Pets, will incorporate VitalZul™ in its pet food line in 2018.

Forward-Looking Statement:

Press Contact

Clifford Price

clifford@PetLifePharma.com

844-473-8543 ext. 701

SOURCE: PetLife Pharmaceuticals, Inc.

EX-99.4 5 ex99-4.htm

PetLife Closes Acquisition of Assets for Dr. Geoff's Real Food for Pets

May 23, 2017

OTC Disclosure & News Service

The product line is projected to include VitalZul™ in a second generation of the product in 2018

HANCOCK, MD / ACCESSWIRE / May 23, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that its subsidiary, Dr. Geoff's by PetLife, Inc. ("Dr. Geoff's by PetLife"), has completed the acquisition of assets related to the natural pet food product line.

The various trademarks supporting the Dr. Geoff's Real Food for Pets™ were acquired in exchange for common stock of the Company.

The Company, through its subsidiary, will implement its plans for a national rollout to the public in the latter part of 2017. The initial flow of products includes canned food and two Superfood Supplements, ImmunoPower™ and Antioxidant Boost™, which should have many benefits for companion pets. PetLife will, over time, roll out a complete product line of 25 foods, treats, supplements, and pet accessories. These include nutraceuticals, shampoos, creams, sprays, and other natural products (i.e. supplements) for dogs and cats.

PetLife projects the inclusion of VitalZul™, the Company's patent pending, non-toxic, bioactive formulation, into a second-generation line of pet food. The active ingredients of VitalZul™ have been shown to have activity against several different cancer cell lines.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company's first product, VitalZul™, is currently in testing. VitalZul's™ active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications. PetLife's acquired brand, Dr. Geoff's Real Food for Pets, will incorporate VitalZul™ in its pet food line in 2018.

Forward looking statement:

This press release contains certain "forward-looking statements," as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Contact

Clifford Price

clifford@PetLifePharma.com

844-473-8543 ext. 701

SOURCE: PetLife Pharmaceuticals, Inc.

EX-99.5 6 ex99-5.htm

PetLife Pharmaceuticals Engages Carter, Terry & Company for Financing of FDA Application

HANCOCK, MD / ACCESSWIRE / May 16, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it has engaged Carter, Terry & Company (“Carter Terry”), a full-service investment brokerage, investing banking, asset management, and banking services firm, to help finance the development of PetLife’s product development and research to fight cancer in pets and the FDA application. The Company seeks to raise $4 million in this series of financing.

“The funds raised will significantly progress the Company toward bringing VitalZul™ to our customers, the families of pets with cancer,” said Dr. Ralph Salvagno, CEO of PetLife Pharmaceuticals. “Our Company is at the forefront of the fight against cancer in pets, and this round of fundraising is a vote of confidence in our product and company vision.”

Founded in 1985 and headquartered in Atlanta, Georgia, Carter Terry has had a consistent pattern of dynamic growth. Carter Terry is a member of the Financial Industry Regulatory Authority (“FINRA”), the Securities Industry Association, and the Securities Investor Protection Corporation.

For more information about Carter Terry, please visit: www.carterterry.com.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company. PetLife’s mission is to bring new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company’s first product, VitalZul™, is currently in testing. VitalZul’s™ active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

About Carter, Terry, & Company

Founded in 1985, Carter, Terry & Company is a full-service investment brokerage, investment banking, asset management and banking services firm that has a consistent pattern of dynamic growth. They are currently one of the largest independent firms in Atlanta, serving clients throughout the country.

Forward looking statement:

This press release contains certain “forward-looking statements,” as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. The economic, competitive, governmental, technological and other factors identified in the Company’s previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Contact

Clifford Price

clifford@PetLifePharma.com

844-473-8543 ext 701

SOURCE: PetLife Pharmaceuticals, Inc.

EX-99.6 7 ex99-6.htm

PetLife Finalizes Negotiations for Dr. Geoff’s Real Food for Pets

Apr 18, 2017

OTC Disclosure & News Service

PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high-potency veterinary cancer medications and nutraceuticals for pets, announced today that it has finalized the negotiations for the acquisition of Dr. Geoff’s Real Food for Pets™. The closing of the acquisition of the trademarked brands and the natural pet food product line is projected to occur within two weeks.

PetLife has expanded plans for a national rollout to the public by Summer 2017 with canned food and two Superfood Supplements, ImmunoPower™ and Antioxidant Boost™, which should have many benefits for companion pets. PetLife will, over time, roll out a complete product line of 25 foods, treats, supplements, and pet accessories. These include nutraceuticals, shampoos, creams, sprays, and other natural products (i.e., supplements) for dogs and cats.

“According to a March 2017 IBISWorld report, rising disposable income, coupled with the tendency for family members to treat pets like family members and an increase in wanting to feed their pets all-natural food, are expected to increase profits for all-natural pet product providers over the next five years,” said Ralph Salvagno, CEO of PetLife Pharmaceuticals. “Additionally, the number of pet-owning households is expected to grow from the current 65% of U.S. households that currently own a dog, increasing the potential consumer demand for Dr. Geoff’s Real Food for Pets™.”

Geoffrey Broderick, Jr., the son of Dr. Broderick, has resigned as President of the Company in order to focus on the development of the Company’s new subsidiary, Dr. Geoff’s by PetLife, Inc. He will bring his experience in the pet food industry and should be instrumental in the Company’s pet product subsidiary as our products go to market, where his focus will be on product distribution channels, the related marketing program, and manufacturing, in line with our anticipated growth.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife’s mission is to bring its new, scientifically-proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, VitalZul™, to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Forward-looking statement:

This press release contains certain “forward-looking statements,” as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. The economic, competitive, governmental, technological and other factors identified in the Company’s previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170418005459/en/

EX-99.7 8 ex99-7.htm

PetLife: Holistic Pet Health is Next Big Trend in Veterinary Medicine

Apr 12, 2017

OTC Disclosure & News Service

As discussed in a recent report by the Company, a health-conscious society is creating the desire for holistic health options for both themselves and their pets. According to the National Center for Health Statistics, Americans spent approximately $30.2 billion in 2012 on holistic health approaches for themselves and their family. With pets increasingly being referred to as members of the family, this demonstrates a trend that will soon impact the pet healthcare industry.

“Over the years, the paradigm shift in veterinary practices to include alternative medicine is directly related to consumer preferences for natural, nonintrusive, and often more affordable wellness solutions,” said PetLife President, Geoffrey Broderick, Jr. “This phenomenon is growing across the globe and current statistics of holistic health adoption are much higher than what is being reported since many veterinarians may not register themselves as offering holistic approaches as part of their practice, simply because they don’t have the time or may not participate in a particular association.” For example, the American Holistic Veterinary Medical Association has approximately 1,000 members in the U.S., yet this growing organization comprises less than one percent of those veterinarians whom currently offer holistic approaches.

Holistic medicine is attractive to pet owners for the same reasons they are attracted to it themselves: It focuses on preventative treatments and the mental and emotional wellbeing of the patient in order to maximize healing. For both humans and animals, holistic approaches may include treatments such as herbal remedies, acupuncture, chiropractic care and massage, homeopathy, and nutrition.

According to a Kroger Co. 2011 survey:

	●	61 percent of pet owners admit they would spend between $100 and $1,000 for life-saving medical treatment.

	●	15 percent would pay between $1,000 and $3,000.

	●	10 percent said they would pay $3,000 or more if necessary.

“The availability of veterinarians that offer holistic health approaches is not meeting the demand from pet owners,” added Dr. Geoffrey Broderick, Chairman of the Product Advisory Board at PetLife. “Traditional health approaches are generally unaffordable for most pet owners, as well as undesirable due to the inherent side effects. Companies like PetLife are striving to fill this gap in the pet care industry by developing and making available nutraceuticals, drugs, supplements, and pet foods that are affordable, non-invasive, eco-friendly, and holistic in nature. Of course, the ultimate goal of natural products is to prolong pets’ lives in the first place and prevent cancer and other diseases prevalent in companion animals.”

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012. PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology—with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Forward looking statement:

View source version on businesswire.com: http://www.businesswire.com/news/home/20170412005301/en/

EX-99.8 9 ex99-8.htm

PetLife: Millennial Pet Owners Leading Charge in Rapid Growth of Holistic Pet Care

Mar 24, 2017

OTC Disclosure & News Service

PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, released today an overview of the main drivers behind the rise of holistic pet care and products. The shift in the pet owner market from baby boomers to health-conscious millennials and an increased access to natural, organic, and eco-friendly pet health practitioners and products are making holistic pet care mainstream. Approximately 56 percent of U.S. households own pets and have such close emotional bonds with their pets that they are often referred to “as family.” This is a major driver of the rapid growth of the holistic pet care industry.

According to Packaged Facts, a leading market research firm,

	●	Millennials make up 1 in 3 current pet owners and are responsible for 43 percent of pet owner growth between 2007 and 2015.

	●	More than half (55 percent) of Millennial pet owners are willing to try holistic and natural-branded nutritional supplements before resorting to conventional pet medication.

	●	Nearly three-quarters (69 percent) of Millennial pet owners are more likely to consider foods whose recipes use naturally-made ingredients over other mass-produced foods.

“The demand for holistic pet care and products is potentially quite higher than what is being reported as these market trends are not tracked every year,” said PetLife President, Geoffrey Broderick, Jr. “Pet owners are more informed and on the lookout for pet care and products that are easy to understand, environmentally friendly, and have formulae designed for enhancing the health of their pets.”

Broderick further stated, “This paradigm shift in consumer preference has even fueled the substantial increase seen in the quantity of holistic veterinary care practitioners over the years, a category still growing both on a national and on an international basis.”

Increased access to holistic pet care and products is a recognition by pet care providers and pet product developers of this demand. In a separate report by Packaged Facts, they highlight the following:

	●	Pet product purchasers, overall, tend to have their day-to-day shopping decisions impacted by an interest in natural/organic/eco-friendly attitudes and environmental/social attitudes, with those consumers who purchase natural, organic, or eco-friendly pet products being even more heavily influenced by these sentiments.

	●	Over half (51 percent) of pet product purchasers feel that natural/organic pet foods are more nutritious than regular pet foods, and 71 percent are willing to spend extra to ensure the wellness of their pets.

“As pets are seen as an essential part of the household, owners are spending more and more to indulge their pets and care for their health,” added Broderick. “Companies like PetLife are striving to develop nutraceuticals, drugs, supplements, and pet foods that are non-invasive, eco-friendly, and holistic in nature to prolong pets’ lives and prevent cancer and other diseases prevalent in companion animals. My father, Dr. Geoffrey Broderick, invented the natural dog food sector almost 50 years ago. The Holistic Pet Health industry is only going to gain a bigger market share in the next few years, and we are excited to be at the forefront of this exciting venture.”

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB:PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012. PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology—with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Forward looking statement:

View source version on businesswire.com: http://www.businesswire.com/news/home/20170324005105/en/

EX-99.9 10 ex99-9.htm

PetLife Supersedes Expectations for the Acquisition of Dr. Geoff’s Real Food for Pets

Mar 21, 2017

OTC Disclosure & News Service

PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it has proceeded to the next expected stage of acquiring Dr. Geoff’s Real Food for Pets™ and simultaneously has expanded plans for a national rollout.

As part of this acquisition, PetLife will assist Healthy Life Pets to roll out a product line of 25 foods, treats, supplements, and pet accessories. These include nutraceuticals, shampoos, creams, sprays, and other natural products (i.e. supplements) for dogs and cats. In addition to canned food, the line already has two existing Superfood Supplements: ImmunoPower™, to help prevent sickness and cancer, and Antioxidant Boost™, which helps rejuvenate the immune system, increase lean muscle, and promote healthy skin and coats.

“We are about to sign our acquisition papers, and PetLife is plunging headfirst into the aggressive expansion of the brand,” said Geoffrey Broderick, Jr., President of PetLife Pharmaceuticals. “Staving off illness in pets starts with everyday necessities like nutrition. By feeding them a healthy, natural food with the proper additional supplementation, pets can live longer and happier lives. My father, Dr. Geoffrey Broderick, has 50 years of experience developing products like these and single-handedly founded the natural pet food industry. No other natural food brand has the history and knowledge that we do.”

Dr. Geoff’s Real Food for Pets™ already includes six SKUs of retail-ready products, including both canned food and antioxidant supplements. Since 1969, renowned veterinarian Dr. Geoffrey Broderick has been a pioneer in the premium, natural pet food industry. Using only superior quality, natural ingredients, Dr. Geoff’s Real Food for Pets™ is based on the dietary needs of pets, not the cost of the ingredients. As an extra benefit, the food is additionally formulated so that both cats and dogs eat the same diet, a rarity in the pet product market.

According to a 2015 study by Innova Market Insights, the demand for natural foods for pets is growing exponentially, with 28 percent of U.S. product launches using a natural positioning, twice the level as compared to the rest of the world. Dr. Geoff’s Real Food for Pets™ is in a prime position to capitalize on this demand, because unlike other pet food brands, the company has almost 50 years of experience and proven results to back up its formula. Dr. Geoff’s Real Food for Pets™, a super-premium natural pet food from the start, actually delivers high-quality dog and cat food made with fresh ingredients, and does not simply claim that it is “natural” solely for marketing efforts.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology—with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170321005550/en/

EX-99.10 11 ex99-10.htm

PetLife Pharmaceuticals Provides an Eye-Opening View on a Recession Resistive Industry

Mar 07, 2017

OTC Disclosure & News Service

PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, released today an overview of the $63 billion companion pet healthcare industry. Empty nesters, reduced fertility, and pet owners prioritizing pet care over their own expenses all contribute to the resiliency of the pet care industry. PetLife’s continuous development of multiple product lines aims to serve the growing companion pet healthcare market, bolstering its market reach and thereby solidifying the company both on a revenue/financial point of view as a natural, solution-focused company.

The pet care industry, from food and treats to veterinary care and boarding, continues to see tremendous growth. All you have to do is walk in to your local PetSmart or pet supply store to see the number of products and accessories available to pet owners; a sure sign of how much Americans adore their pets.

Data from various research reports shows a staggering growth in pet spending:

	●	$8.4 billion in 1980
	●	$17 billion in 1994
	●	$63 billion in 2016

This data falls in line with the American Society for the Prevention of Cruelty to Animals (ASPCA) report which indicates almost half of American households own a dog and around a third are cat owners. A graphical representation of this data is available here: https://fred.stlouisfed.org/series/DPETRC1A027NBEA.

Studies have shown that during recessions and tough times, pet owners will cut back on their own expenses to continue to provide for their animals. Additionally, offspring from the Baby Boom generation are “leaving the nest,” and their parents are filling in the empty space with companion pets. Furthermore, reduced fertility in America is also contributing to the growing pet industry, as single (and no-children) households tend to have a higher rate of pet ownership.

“Aside from making great companions, our household pets can actually point our business compass to fantastic investment opportunities,” said PetLife CEO, Dr. Ralph Salvagno.

As pets are seen as an essential part of the household, owners are spending more and more on end-of-life healthcare as pets age. Companies like PetLife are striving to develop products that are non-invasive and will prolong pets’ lives with a smaller price tag for pet owners. In fact, The Motley Fool predicts that as the U.S. gets wealthier, there will be a trend to spend more money on life-extending therapies for pets, something that was less common 20 years ago.

Dr. Geoffrey Broderick, Sr., a world-famous veterinarian, spent the last 50 years developing the products to help prevent cancer and significantly prolong the lives of pets all around the world. He currently serves as Chairman of the Product Development Committee for PetLife.

“They’re the quintessential part of a constantly growing economic sector that shows no sign of slowing down, and because it’s based on the hard-wired human instinct to care for our loved ones, it’s more or less recession-proof,” added PetLife President, Geoffrey Broderick, Jr.

Speaking at a recent press conference, Geoffrey continued: “My family for the past 50 years has been involved with developing nutraceuticals, drugs, supplements, and pet foods with the intention of stopping and preventing cancer and other diseases prevalent in companion animals. The industry has grown tremendously, but some of the most significant growth has been in the nutritional segment of the sector to promote pet health through prevention and cure. Our goal with PetLife is to build a cutting-edge pet pharmaceutical/nutraceutical company addressing the multiple diseases prevalent in the lives of pets. With our extensive history in this industry, we will develop multiple products that will add to the quality of pet lives all around the globe.”

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB:PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife's mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology—with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company's business prospects and performance. The Company's actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company's filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170307005496/en/

EX-99.11 12 ex99-11.htm

PetLife Pharmaceuticals Signs Letter of Intent to Acquire Healthy Life Pets Brand

Feb 28, 2017

OTC Disclosure & News Service

PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it signed a Letter of Intent to acquire the assets of Healthy Life Pets. Most commonly known as Dr. Geoff’s Real Food for Pets™, assets in this brand include six SKUs of retail-ready products, including both canned food and antioxidant supplements.

“Dr. Geoff’s products are some of the best in the world, and the pet food line will be a welcome addition to the growing PetLife portfolio,” said Ralph Salvagno, M.D., CEO of PetLife Pharmaceuticals. “Through extensive research based on our pets’ ancestral diets, Dr. Geoffrey Broderick has proven that when dogs and cats ate the same wild, fresh fare before manufactured pet food, they lived longer.”

This acquisition will allow PetLife to benefit from almost a half-century of research and development. Additionally, it will save PetLife and its shareholders the substantial cost normally seen in the development of a product of this magnitude, being that the current Dr. Geoff’s product line is market ready.

According to the President of PetLife Pharmaceuticals, Geoffrey Broderick, Jr., “Dr. Geoff’s Real Food for Pets™ is the next generation of my father’s famous Cornucopia Pet Foods, which started the entire natural pet food industry, and this means that Dr. Geoff’s is almost 50 years in the making. My father, Dr. Broderick, has reached national and international acclaim for his lifetime of revolutionary work and his success in the nutritional pet industry. Now Dr. Geoff’s will be his veterinary legacy, while providing the building blocks for future nutraceuticals currently under development by PetLife (with Dr. Geoff’s simultaneously maintaining its brand continuity). PetLife Pharmaceuticals was founded with the same mission of helping pets live longer, healthier lives, and this acquisition will bring us one step closer to fulfilling that goal.”

Since 1969, renowned veterinarian Dr. Geoffrey Broderick has been a pioneer in the premium, natural pet food world. Using only superior quality, natural ingredients, Dr. Geoff’s Real Food for Pets™ is based on the dietary needs of pets, not the cost of the products. The food is formulated so that both cats and dogs eat the same diet, a rarity in the pet product market. In addition, Dr. Broderick has developed two groundbreaking Superfood Supplements: ImmunoPower™ and Antioxidant Boost™ Superfoods.

“This acquisition will allow us to make Dr. Geoff’s Real Food for Pets™ available to pets nationwide,” said Todd Cook, CEO of Healthy Life Pets. “Dr. Broderick has developed a food that’s a smarter and healthier choice for both pets and their owners’ wallets. Our food has more nutrition and healthier fat from animal proteins and less broth or water, which results in a higher concentration of nutrients for pets, equating to less food needing to be consumed daily.”

The closing of the transaction is expected before April 30, 2017.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170228006091/en/

EX-99.12 13 ex99-12.htm

PetLife Pharmaceutical Taps National Public Relations Firm to Help Bring to Market Cancer Treatment Originally Developed by Cuba

Feb 21, 2017

OTC Disclosure & News Service

PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it has retained Gregory FCA Communications, Inc., one of the nation’s largest public relations agencies, to help bring to market a breakthrough cancer treatment for pets produced from the venom of the blue scorpion.

Venom from the blue scorpion, which is native only to Haiti, Cuba, the Dominican Republic, and Venezuela, has been used for more than 20 years in Cuba to treat cancer patients. Blue scorpion venom is one of the most expensive liquids in the world.

PetLife Pharmaceuticals is embarking on a series of clinical trials for its use in pets here in the U.S. The announcement comes on the heels of PetLife Pharmaceuticals’ appointment of Dr. R. Geoffrey Broderick as Chairman of Product Development. As one of the world’s most famous veterinarians, Dr. Broderick is considered the father of the natural pet food industry and who has been working for the past 50 years to reduce and prevent cancer in dogs and cats.

“Nearly 13 million pets receive a cancer diagnosis each year, and for many it’s a death sentence,” begins Dr. Broderick. “Nearly 50 percent of pets age 10 and over will die from cancer. Current treatments—including surgery and chemotherapy—are heinously expensive, barbaric, and riddled with side effects. PetLife Pharmaceuticals is the first organization in the world to investigate the use of scorpion venom as a non-toxic treatment for cancer, which has the promise of saving millions of pets, while improving the quality of life for both pets and their owners.”

“PetLife Pharmaceuticals’ commitment to saving pets lives through this novel therapy is filling a desperately needed unmet medical need in veterinary care,” says Greg Matusky, president and founder of Gregory FCA. “It’s critically important that this drug becomes available to pets and their owners here in the U.S., considering the opening of relations with Cuba and recent acceptance of many medical discoveries made there.”

For instance, last fall, Roswell Park Cancer Institute in Buffalo, New York won the right to conduct the first FDA-sanctioned study of a vaccine to treat lung cancer in humans. PetLife Pharmaceuticals sees similar parallels in its development of cancer therapies in pets.

“The advancement of this drug will serve as the culmination of more than 50 years of my work in veterinary medicine and the heartbreak I see played out over and over again with the loss of life and its devastation to families,” continued Dr. Broderick. “PetLife Pharmaceuticals is working hard to produce the venom, conduct the clinical trials, and reduce the incidences of cancer in pets.”

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

About Gregory FCA

A full-service, strategically integrated firm, Gregory FCA creates and deploys sophisticated national media relations, social media, content marketing, investor relations, and financial communications campaigns.

The nation’s 50^th largest PR firm, our clients include fast-growing private and publicly traded companies competing in today’s digital economy. Gregory FCA’s staff of 57 professionals—drawn from journalism, finance, communications, and public relations—service many key markets, including financial services, consumer and enterprise technology, real estate, healthcare and consumer products, and more. For more information, visit www.gregoryfca.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170221005610/en/

EX-99.13 14 ex99-13.htm

World Renowned Veterinary Nutritionist Dr. R. Geoffrey Broderick Continues Groundbreaking Efforts to Help Animals by Joining PetLife Pharmaceuticals, Inc. as the Chairman of Product Development and Advisory Board

Feb 09, 2017

OTC Disclosure & News Service

Hancock, MD, Feb. 09, 2017 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, augments the advisory board and prepares for new and expanded product lines with the appointment of Dr. R. Geoffrey Broderick as Chairman of Product Development.

Dr. Broderick, one of the world’s most famous veterinarians, comes to PetLife with an intricate knowledge of the pet industry, He is a practicing veterinarian with over 48 years’ experience as an international expert, and is also a professional developer of organic pet food, pet supplements, and other pet products, including the first natural pet food, the first snack for senior dogs, the first dietary formula, and the first antioxidant supplement.

Besides these preventative revolutionary inventions, he also prevailed in his veterinary career with many awards and other accreditations. He was the first in history to dissolve urinary stones without antibiotics, for which he is the recipient (and the youngest to ever receive) the Award by the Committee for World Health, which was presented on the 50^th anniversary for the discovery of Vitamin C (in Palm Springs CA, 1978). In fact, this revolutionary work was eventually incorporated in his subsequently developed Cornucopia Natural Pet Products in order to provide the proper PH of urine to prevent struvite (triple phosphate) urinary stones from happening in the first place.

The impressive background and experiences Dr. Broderick brings to PetLife began in New York City, in 1941, where he was born. Having served in Korea with the US Army as a paratrooper, Dr. Broderick returned stateside to pursue veterinary medicine, graduating from Kansas State University in 1969 at the top of his class. After opening the Southdown Animal Clinic in Huntington, NY, he started the Natural Pet Food movement in America when speaking at the Health and Nutrition Expo in New York City after being brought to the podium by the legendary William Dufty, the author of Sugar Blues. It is here that Dr. Broderick made what is now considered a world-wide major historical impact by declaring the national movement against sugar and chemicals in pet food.

Cornucopia Natural Pet Food was launched by Dr. Broderick in the early 70’s. This, being the start of an entire new pet category, began a major revolution in the Pet Food industry as Dr. Broderick went on to formulate additional foods and supplements for the prevention of pet diseases. Super-Food and Phyto-Food supplements were invented, as he, working with his son, Geoffrey Broderick, Jr., developed the very first antioxidant products. “Getting an early start in what would become a very successful Product Development career, I was excited to be working with my dad to develop these products, which were years ahead their time, long before the word ‘antioxidant’ was commonly known,” said Geoffrey Jr, whom recently became the President of PetLife.

Dr. Broderick commented, “My dedication to the companion animal industry, from veterinary medicine to food formulator and nutritionist, has continued to see boundaries pushed and new breakthroughs found. PetLife is further pushing those boundaries once again, and I am ecstatic to be able to lend my experiences and knowledge to the furtherance of Vitalzul™, its companion nutraceuticals, and to grow the company with additional product lines in several classes of trade.”

“We welcome Dr. Broderick to the team with open arms. PetLife, having completed the 1^st of 3 studies in its pre-INAD protocol, is ready to break the mold of conventional veterinary care and existing food and supplement products. The addition of Dr. Broderick puts us one step closer to reaching that goal,” commented Dr. Salvagno, CEO of PetLife.

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

Safe Harbor

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.14 15 ex99-14.htm

PetLife Pharmaceuticals Announces Son of World Famous Veterinarian & Pet Industry Innovator, Geoffrey Broderick, to Join the Company as the New President

Feb 03, 2017

OTC Disclosure & News Service

Hancock, MD, Feb. 03, 2017 (GLOBE NEWSWIRE) — PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to announce the addition of Geoffrey Broderick, who comes to PetLife with extensive experience in the pet industry, as the new company President.

Mr. Broderick, with over 25 years of business experience and multiple degrees, is a Product Development expert, a Business Consultant, and a Legal Advisor. Having augmented his professional expertise on state, national, and international levels, Broderick has also had a substantive career well beyond his professions. As a commissioned officer in the Army National Guard and a graduate from Officer Candidate School with honors, Mr. Broderick has valuable leadership skills and the mental strength of a soldier. His father, Dr. Geoffrey Broderick, DVM, invented the first natural pet food (Cornucopia), and is considered the world’s most famous veterinarian. Thus, Geoffrey started off his Product Development career early on by helping to develop and expand this brand new (Natural) pet category, which eventually became a multi-billion-dollar industry.

Geoffrey went on to develop the very first Antioxidant Supplement for pets (Cornucopia Super-Food.) Eventually, he also formulated, designed, and created the very first super- premium wild bird food, which ended up becoming the official bird food of the National Wildlife Federation—the largest wildlife organization on the planet. Over the years, he has used his talents, education, and experience to successfully lead several other companies, organizations, and firms through all stages of their transitional development. PetLife expects to quickly capitalize on Geoffrey’s experience, talents, connections, and family history.

With his dad being a world-renowned veterinarian, pets have always been a significant part of Geoffrey’s life. His interest in PetLife stems from his love for animals and the realization that he “is on the ground floor of the next big thing,” according to Geoffrey. “My dad has spent the last 50 years developing the products to help prevent cancer and significantly prolong the lives of pets all around the world, so when I heard about PetLife, how could I not get involved with a company that shares the same vision that my family had for over 50 years in developing nutraceuticals, drugs, supplements, and pet foods with the intention of stopping and preventing cancer and other diseases prevalent in companion animals.” He went on to explain in a recent press conference, “Our goal is to build a cutting-edge pet pharmaceutical/nutraceutical company addressing these multiple diseases. With my family’s extensive history in this industry, we have grand plans to develop multiple products.” Geoffrey is excited about all the proposed products that PetLife will be developing this year. “Having my thumb on the pulse of the pet industry,

my family immediately recognized this huge opportunity. Our family pioneered the preventative nutritional journey for pets, and I’m happy to once again be part of the continued expedition toward the battle my dad set out to end so long ago.”

Alongside his business expertise and professional proficiencies, Geoffrey is also academically well-accomplished, and (with several degrees, including an MBA and Doctorate) he feels he can bring his corporate experience and Product Development skills to the core of PetLife. He stated, “I don’t believe I’ve ever seen a company with such potential, while at the same time being such a perfect fit for everything I can bring to the table.” He adds, “I’m ready to make a difference!”

Dr. Salvagno, PetLife CEO, commented “PetLife is gaining worldwide attention in the pet industry, and Mr. Broderick recognizes the potential of our strong future. Mr. Broderick and his family’s extensive knowledge, proven success, and hands-on industry experience will certainly prove to bring tremendous value to our company.”

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife's mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, VitalzulTM, to the world of veterinary oncology—with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.15 16 ex99-15.htm

PetLife Pharmaceuticals reports the First of Three Preclinical Studies in their pre-INAD Process for Vitalzul. Blue Scorpion Venom Toxicity Study Results Show No Adverse Reactions across Multiple Dosing Levels.

Jan 10, 2017

OTC Disclosure & News Service

Hancock, MD, Jan. 10, 2017 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, received the initial Acute Toxicity study results, part of the pre-INAD and FDA/CVM submission protocol.

This is a first of its kind study, confirming PetLife’s in-house research on Venenotherapy, with Blue Scorpion venom, having no toxic side effects.

As part of the pre-clinical study protocol, our Blue Scorpion venom formulation was evaluated in an Acute Toxicity study in mice ⁽¹⁾. After administration for 14 days at 1X, 5X and 10X times dosing, the Blue Scorpion venom formulation was well tolerated and no adverse effects were observed at any of the dosing levels. All study animals gained weight as expected based on clinical observation and upon necropsy, there was no evidence to suggest any gross organ pathology.s

Preparations for the Cell Line and Pharmacokinetic (PK) and Pharmacodynamic (PD) studies are now underway. These studies are required to meet and file the INAD application with the FDA/CVM. PetLife anticipates completing these studies and filing the application within the next 6 months.

“We are excited to announce the stellar results of our first toxicity study with our partner InnoVision. This study sets the stage for the next steps in preparation for FDA/CVM submission of PetLife’s “Vitalzul™”, including upcoming Cell Line Studies and additional toxicity studies. Cell lines to be investigated include glioma, bladder and lung cancers, additionally, hematological malignancies will be studied” stated Dr. Salvagno, CEO of PetLife Pharmaceuticals.

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

(1) In partnership with InnoVision Therapeutics; VP, Research & Drug Development from InnoVision, Dr. Daniela Maslennikov

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife's mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology -- with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.16 17 ex99-16.htm

Correction: PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line

Dec 07, 2016

OTC Disclosure & News Service

Hancock, MD, Dec. 07, 2016 (GLOBE NEWSWIRE) — PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to announce the results of a product expansion meeting with InnoVision Therapeutics, our partner for the Vitalzul™ FDA/CVM submission.

The market for Pet medicines, supplements, food and treats is ever growing. According to the American Pet Products Association (APPA), the U.S. Pet Industry expenditures surpassed $60B in 2015⁽¹⁾.

Breakdown:

Food			$23 Billion

Supplies/OTC Medicine			$14 Billion

Vet Care			$15 Billion

Live animal purchases			$2 Billion

Pet Services: grooming & boarding			$5 Billion

With this in mind, the management of both companies met to discuss expanding Petlife’s existing product line with additional natural based products that InnoVision has already formulated and produced for the human market. These products have a veterinarian application and address some of the most common medical conditions seen in companion pets. The demand for natural based products continues to rise as pets are living longer and serious life threatening diseases are becoming more prevalent. Working with InnoVision may allow PetLife as a new biotech company to begin generating revenues ahead of the anticipated FDA/CVM approval of its core product, Vitalzul™.

A small sampling of the initial product line targets:

Hepato-protective (digestive and liver protection)

Antioxidants (improves immune system)

Anti-inflammatory and analgesics

Dr. Salvagno commented “Our focus with PetLife has always been to provide multiple natural based products addressing the most common medical conditions in our companion pets. Our desire to expand our product offerings is designed to meet the increasing demand in both the US and European markets for natural based solutions for these growing issues in pets. The goal is to have an increased menu of unique products ready in 2017 for market, prior to the anticipated FDA/CVM approval of Vitalzul™.”

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

1.Pet Industry Market Size & Ownership Statistics http://www.americanpetproducts.org/press_industrytrends.asp

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology — with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.17 18 ex99-17.htm

PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line

Dec 07, 2016

OTC Disclosure & News Service

Breakdown:

Food			$23 Billion

Supplies/OTC Medicine			$14 Billion

Vet Care			$15 Billion

Live animal purchases			$2 Billion

Pet Services: grooming & boarding			$5 Billion

With this in mind, the management of both companies met to discuss expanding the existing product line with additional natural based products that InnoVision has already formulated and produced for the human market. These products have a veterinarian application and address some of the most common serious medical conditions seen in companion pets. The demand for natural based products continues to rise as pet owners are living longer and serious life threatening diseases become more prevalent. Working with InnoVision may allow PetLife to begin generating revenues ahead of the anticipated FDA/CVM approval of its core product, Vitalzul™.

A small sampling of the initial product line targets:

Hepato-protective (digestive and liver protection)

Antioxidants (improves immune system)

Anti-inflammatory and analgesics

Dr. Salvagno commented “Our focus with PetLife has always been to provide multiple natural based products addressing the most common serious medical conditions in our companion pets. Our increase in product offerings is designed to meet the increasing demand in both the US and European markets. The goal is to have a menu of selective products ready in 2017 for market, prior to the anticipated FDA/CVM approval of Vitalzul™.”

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

1. Pet Industry Market Size & Ownership Statistics http://www.americanpetproducts.org/press_industrytrends.asp

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology — with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.18 19 ex99-18.htm

PetLife Pharmaceuticals’ CEO Dr. Salvagno Provides White Paper on “Venenotherapy” While Preparing for FDA Submission

Dec 06, 2016

OTC Disclosure & News Service

Hancock, MD, Dec. 06, 2016 (GLOBE NEWSWIRE) — PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to provide a White Paper written by CEO Dr. Salvagno on ‘Venenotherapy’ and additional market statistics.

Animal specific drugs are rare, especially in the oncology field. According to the American Pet Products Association, about 65% of US households own at least one pet, an estimated 86 million cats and 78 million dogs, among other animals. PetLife’s Vitalzul(tm) is going through pre-INAD studies ahead of FDA/CVM submission for this expansive market.

White Paper on Venenotherapy: http://www.petlifepharma.com/investor-relations.php

“Excitement in the company continues to grow as we await the pre-INAD study results for our dosing and preliminary toxicology of Vitalzul™ later this month. FDA/CVM submission of Vitalzul™ with the expert help of InnoVision Therapeutics will follow the pre-INAD studies” stated Dr. Salvagno, CEO of PetLife.

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology — with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.19 20 ex99-19.htm

PetLife Pharmaceuticals Updates Shareholders on the Company Progress with Vitalzul™ Studies and Additional Product Offerings

Dec 01, 2016

OTC Disclosure & News Service

Hancock, MD, Dec. 01, 2016 (GLOBE NEWSWIRE) — PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to provide a Shareholder update.

Dear Fellow Shareholder,

Your company continues to make progress with the development and testing of our flagship product Vitalzul™. The PetLife team has recently presented at Investor conferences in San Francisco, Toronto, Dallas, Las Vegas and Boston and has plans to present our company next month in Los Angeles. Additionally, we will be presenting to investors during the JP Morgan conferences in early 2017.

We continue with our pre-INAD studies and are pleased that we will have our dosing and preliminary toxicology studies of Vitalzul™ completed by mid to late December. Armed with those studies we then plan to discuss our Clinical and Regulatory program with the FDA/CVM. We are also building out our portfolio of product offerings and will soon announce several new natural based veterinary products.

We continue to monitor the world literature and have noted a recent manuscript from Saudi Arabia outlining the positive effects of scorpion venom on a number of cancer cell lines. This supports our current efforts in partnership with InnoVision.

The market has recently been a bit harsh with our stock. Low trading volume can often result in extreme volatility and we certain have seen this recently. This volatility does not affect the core mission of the company but certainly is concerning to management. We are making efforts to support our stock price by continuing our pre-INAD studies on an aggressive schedule and by presenting our message through social media and investor presentations.

Our mission at PetLife Pharmaceuticals is critically important to the health of our companion animals. I ask that you continue to support the company and help spread the message. Additionally, with the pull back in stock price, it is an excellent time to show your support by purchasing additional stock (OTCQB: PTLF) for your portfolio.

If you haven’t visited our website (www.petlifepharma.com) or our Facebook page (https://facebook.com/PetLifePharmaceticals) recently please take a minute to do so today and invite your friends and acquaintances to support our mission.

Ralph T Salvagno M.D.

CEO PetLife Pharmaceuticals Inc.

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology — with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.20 21 ex99-20.htm

PetLife Pharmaceuticals Notes Recent Cuban Research Providing Profound Evidence of Caribbean Blue Scorpion Venom’s Ability to Eradicate Cancer Cells as Continued Support for PetLife’s pre- INAD Studies of Vitalzul™

Nov 15, 2016

OTC Disclosure & News Service

Hancock, MD, Nov. 15, 2016 (GLOBE NEWSWIRE) — PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, has been pleased with the existing studies coming out of Cuba and is looking forward to additional research of the benefits of Blue Scorpion venom. The market for natural products for human Cancer treatment has been big business in Cuba.

Cuban researchers have published studies demonstrating the efficacy of the venom extract of the blue scorpion (Rhopalurus junceus) in the Journal of Venom Research ⁽¹⁾. This human study demonstrates the efficacy across many Cancer Cell lines. Additional studies have been undertaken to characterize Rhopalurus junceus venom in other international journals ^{(2), (3), (4)}. These studies support the efforts of PetLife Pharmaceuticals to bring an FDA/CVM approved, prescription strength, clinically proven Blue scorpion venom product to market for the treatment of cancer in companion animals, Vitalzul™.

Dr. Salvagno, CEO of PetLife Pharmaceuticals noted “PetLife will continue on our path, through our current pre-INAD studies and subsequent application to the FDA/CVM, to secure approval of our patented prescription strength formulation of blue scorpion venom “Vitalzul™”. These studies from Cuba support our work, but we will clearly move forward with appropriate studies to confirm efficacy, dosing and safety to allow distribution of a therapeutic drug to the US and international markets.”

These manuscripts can be found on our website www.petlifepharma.com

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

	1.	In Vitro anticancer effect of Venom from Cuban Scorpion Rhopalurus junceus against a panel of human cancer cell lines. Diaz-Garcia et al. J Venom research (2013), Vol. 4, 5-12

	2.	Enzymatic analysis of venom from Cuban scorpion Rhopalurus junceus. J Venom Research (2015), Vol. 6, 11-18

	3.	Biochemical and molecular characterization of the venom from the Cuban Scorpion Rhopalurus junceus. Garcia-Gomez et al. Toxicon (2011), Vol. 58, 18-27

	4.	The Cuban scorpion Rhopalurus junceus (Scorpion Buthidae): component variations in venom samples collected in different geographic areas. Rodriguez-Ravelo et al. J Venom Anim Toxins Incl Trop Dis (2013), Vol. 19, 13-24

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology — with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.21 22 ex99-21.htm

PetLife Pharmaceuticals and Lumleian, LLC Announce Partnership to Advance Development and Commercialization of Promising Veterinary Health Pipeline

Oct 27, 2016

OTC Disclosure & News Service

Hancock, MD, Oct. 27, 2016 (GLOBE NEWSWIRE) — Hancock, MD - Innovative veterinary health company, PetLife Pharmaceuticals, Inc. (OTC QB: PTLF), announced today a partnership with Lumleian, LLC, a life sciences advisory firm based in Boston, MA. Working together, PetLife and Lumleian will seek to advance PetLife’s clinical and commercial pipeline in the United States, including securing capital to develop its lead product, Vitalzul™, for the treatment of various veterinary oncology indications.

Dr. Salvagno, CEO of PetLife Pharmaceuticals, noted, “Biopharmaceutical companies like PetLife need an experienced partner to assist in the optimization of our development strategy and enhancement of shareholder value by market identification and capital acquisition. After evaluating several potential partners, we are confident that our choice of Lumleian will serve the company well. Lumleian’s experience and track record with similar companies gives us the additional firepower we need to move our company forward.”

Lumleian has a strong track record of working with companies and investors to identify synergies and facilitate the development and commercialization of innovative life sciences technologies. “We are excited to work closely with the PetLife team to bring to market therapies and products that serve a significant unmet need and that have the potential to change the treatment paradigm for cancer in pets,” said Jason Greenberg, a Director of Lumleian.

“We see a largely untapped opportunity in the veterinary space to deliver safe and effective treatments for pets and their owners. We believe PetLife can be a leader in this space, and with the right strategic relationships, it can seize this opportunity as a first mover,” said Greenberg. “We evaluate development-stage companies all the time. PetLife’s unique value proposition, in our view, is driven by the relatively clear path to technical and regulatory success. With the strong human data and preclinical animal work generated to date, Vitalzul™ offers a compelling investment thesis,” continued Greenberg.

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology — with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

About Lumleian, LLC

Lumleian is a Boston based life sciences consultancy serving the biopharmaceutical industry by providing strategic advisory services across the gamut of the life sciences. Lumleian has successfully facilitated numerous investments by working closely with companies it determines offer a strong value proposition and which serve a significant unmet need. For more information, please visit http://www.lumleian.com

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.22 23 ex99-22.htm

PetLife Pharmaceuticals Announces the Addition of a Seasoned Marketing Specialist and Investor, Mrs. Vyvyan Campbell, to the Board of Directors

Oct 24, 2016

OTC Disclosure & News Service

Hancock, MD, Oct. 24, 2016 (GLOBE NEWSWIRE) —

PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, prepares the company for growth and the exciting road ahead with the addition of Mrs. Vyvyan Campbell to the Board of Directors.

The production of the two PetLife informational and testimonial videos currently released to the market were directed and produced by Mrs. Campbell and her accomplished production company:

Testimonials: https://youtu.be/JjANIT17210

Vitalzul™ Organic Health for Pets: https://youtu.be/_yqZ1Gbm4hw

Mrs. Vyvyan Campbell

Mrs. Vyvyan Campbell’s diverse career in television and film spans over 30 years and several continents. Since forming her own production company, JV Productions, in 1997, Vyvyan has achieved a sterling reputation in North America for producing hit TV series. She has both produced and been an executive producer on over a dozen series, including the hit series Selling New York and Selling L.A. on HGTV US, and more recently JV’s new series on Bravo: Yours, Mine or Ours.

Pets have always been a big part of Vyvyan’s life. Her interest in PetLife stems from her love of animals. The love of her life is her nine-year-old Chihuahua named Pip. “I couldn’t bear the thought of Pip getting cancer and going through all the horrible side effects of today’s traditional treatment solutions. I have spent years taking care of a loved one that has suffered from cancer and have experienced all of the terrible side effects of Chemotherapy and Radiation first hand. I would never put Pip through it. So, when I heard about PetLife’s Vitalzul drug and complimentary preventative product line that will hopefully reduce, if not eliminate Pip’s risk of getting cancer, how could I not get involved both as a pet owner and an experienced marketer?”

Vitalzul™ cancer treatment is just one aspect of what can be done with this formula and Vyvyan is excited about the other companion products that PetLife has planned for 2017. Vyvyan feels she can bring her experience of running a large company and, in particular, her marketing skills to the board of PetLife. “It is such an amazing opportunity and really brings great value to the world and in particular to our pets” she comments.

“The addition of Mrs. Campbell to our team is going to make PetLife, Vitalzul™ and its line of complimentary pet products a household name in the companion animal marketplace. She brings experience in running a large company and savvy media knowledge. Building our board of directors with business leaders and strong minds is part of our fiduciary duty to our shareholders,” commented Dr. Salvagno, CEO of PetLife.

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology — with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.23 24 ex99-23.htm

PetLife Pharmaceuticals Announces the Addition of Dr. Simon Wood PhD as the Company’s new Scientific Officer with plans to expand its Current Portfolio of Veterinarian Drugs and Nutraceuticals

Oct 20, 2016

OTC Disclosure & News Service

Hancock, MD, Oct. 19, 2016 (GLOBE NEWSWIRE) — PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, expands management with the addition of Dr. Simon Wood PhD, a seasoned scientist that will help expand PetLife’s product line with new patents and drugs.

Simon Wood PhD, FRSC(UK), CChem, CSci

Dr Wood is an Adjunct Professor at the University of British Columbia, Food, Nutrition and Health Program and an Adjunct Professor at the School of Public Health, Faculty of Health Sciences, Curtin University, Australia. He has over 35 years of experience gained on three continents managing chemical companies, developing proprietary natural products and their global markets and lecturing at a medical university.

He has worked on the science behind various natural products for the last 15 years from start-ups to multinational; developing data for safety, pre-clinical, human trials, regulatory status and patents. He has published over 30 peer reviewed papers and has several patents.

His interests are in developing science on natural products from structural identification through preclinical studies to human trials at CRO’s and Universities around the world and then using these to attain status with regulators globally that helps facilitate sales. Other interest involves combining natural products with Pharmaceutical products.

PetLife’s CEO, Dr. Salvagno, commented “The addition of Dr. Wood to our team will expand our internal knowledgebase of the industry and the potential reach of PetLife in the veterinarian pharmaceutical space. It is critical for the growth of our company to have a pipeline of new drugs. New drugs and patents are important to the success of the company and in building shareholder wealth. The goal of PetLife was never to be a single product company. Dr. Wood will assist the company in researching potential drugs for PetLife to acquire or develop that would immediately expand the company's pharmaceutical product line. One of these potential drug candidates under consideration and review is already in Phase 3 trials on the human side and would potentially have a big impact in Veterinarian medicine. The additional products we are researching and already negotiating with address the most common diseases and complications in our companion pets.”

Dr. Wood stated “When I first looked at PetLife I knew this team of professionals were on to something big. There is a vacancy in this space and room for a young, lean company to make big inroads quickly. The key focus now will be getting the company's core product Vitalzul™ registered with the FDA/CVM. My task will be assisting with this in sharing many years of industry knowledge. I will be researching, evaluating and helping to secure and patent additional opportunities the company is considering now. There are many exciting opportunities and timely plays in this space and I am very excited to join the team on this mission.”

Dallas Money Show: Oct 19 – Oct 21, 2016

Speaker Schedule: Dr. Salvagno, 11:30am-12:15pm Oct 21, 2016

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife's mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology — with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company's business prospects and performance. The Company's actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company's filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.24 25 ex99-24.htm

PetLife Pharmaceuticals is Pleased to Announce the Completion of the New Company Website

Oct 17, 2016

OTC Disclosure & News Service

Hancock, MD, Oct. 17, 2016 (GLOBE NEWSWIRE) — PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, has completed the corporate website overhaul as FDA/CVM submission and testing nears.

In conjunction with the hiring of InnoVision, rebranding of Escozine for Pets as Vitalzul™ and in preparation for the FDA/CVM process, management felt a clean, modern design website with easy navigation and helpful tools for pet owners, investors and veterinarians was warranted. Please check out the new PetLife Pharmaceutical website: http://www.petlifepharma.com/

PetLife’s website offers a complete overview of the company, including corporate news, stock price and chart, as well as testimonials, vet endorsements and details on Vitalzul™:

-Science behind Vitalzul™

-The Patent

-Oncological treatment including post FDA/CVM product lines

-PetLife’s nutraceutical lines

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology — with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.25 26 ex99-25.htm

PetLife Pharmaceuticals Expands Cell Line Study with InnoVision in Preparation for FDA/CVM Registration Submission

Oct 13, 2016

OTC Disclosure & News Service

Hancock, MD, Oct. 13, 2016 (GLOBE NEWSWIRE) — PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to announce expansion of testing of Vitalzul™ as part of their pre-INAD studies.

In partnership with InnoVision Therapeutics, PetLife Pharmaceuticals announces the continuation of their advanced research in the pharmacological study of Vitalzul™ including toxicity, cell line and PKPD (pharmokinetics and pharmodynamics) studies in species that are symmetrical at molecular level to their target companion animal species. The studies will be conducted both via GLP and non-GLP methods as per the international standards addressing the targets.

PetLife and InnoVision expect results of their Rat Toxicity Studies within the next 30 days, allowing for progression to the Dose Range Finding Toxicology Studies for the next series of investigations. These studies are being undertaken as part of PetLife’s pre-INAD program in anticipation of a meeting with the FDA/CVM for discussion of PetLife’s Clinical and Regulatory Pathway for Vitalzul™’s registration process. These dosing parameters will also help the company advance their complimentary food and treat products using Vitalzul™ as an essential ingredient.

These additional products, currently under development, are anticipated for release in first quarter 2017. The new products will focus on providing a healthier food for companion pets. One food line will be produced for pets of all ages and a second premium line will be produced to address the needs of senior pets. Statistics show that 50% of cats and dogs will develop cancer after the age of 10. PetLife believes that starting these pets on our product by the age of 7 and combining it with a healthier mixture of food will reduce these odds significantly. Vitalzul™ Pet Foods will be boosted with both an immunity vitamin package and PetLife’s proprietary nutraceutical line, Vitalzul™, embedded directly in the food. The company will be discussing more details on this upcoming launch in coming news.

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology — with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.26 27 ex99-26.htm

PetLife Pharmaceuticals is Pleased to Showcase its New “Vitalzul™ Information Video” along with a Corporate Update

Oct 10, 2016

OTC Disclosure & News Service

Hancock, MD, Oct. 10, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to provide a detailed information video on Vitalzul™.

PetLife is excited to release its new Vitalzul™, Organic Health for Pets video: https://youtu.be/aaIDk-ufjgk (YouTube version) and https://goo.gl/B9aEGd (Dropbox version)

The Vitalzul™ video includes testimonials, veterinarian discussions of the treatment process by Dr. Mitchell, PetLife’s VP of Veterinary Affairs, and a discussion by Dr. Salvagno, CEO of PetLife Pharmaceuticals. The video highlights the urgency in addressing this cancer epidemic in pets and the lack of affordable solutions available in the market today. Vitalzul™ hopes to address this need globally by providing an affordable, natural solution for our companion pets with no known negative side effects. In America alone, an estimated 11,000,000 pet owners chose euthanasia last year over a costly and toxic oncological treatment regiment. The toxicity of conventional drugs like chemotherapy may kill the pet before the cancer.

“I am excited to be part of PetLife and Vitalzul™’s product development and testing. The results we are seeing with our patients are fantastic. Now that pre-INAD studies have begun, we are on our way towards FDA/CVM submission” stated Dr Mitchell, PetLife’s VP of Veterinary Affairs.

In preparation for the FDA/CVM process, the company has retained the services of InnoVision Therapeutics, a seasoned company, whose principals have decades of success in successfully registering a variety of drugs with the FDA/CVM. They will be navigating the pathway through the FDA/CVM registration process for PetLife’s leading drug Vitalzul™. In addition, Petlife Pharmaceuticals has rebranded the drug and changed the name from Escozine to Vitalzul™. Last week, management completed the restructuring of PetLife’s share structure, with the final step being the removal of the D designation. The designated symbol on the OTCQB is PTLF.

Petlife’s 506 Private Placement Memorandum is available only to accredited investors.

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology -- with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.27 28 ex99-27.htm

PetLife Pharmaceuticals Announces pre-INAD (Investigational New Animal Drug) Cell Lines Study of Vitalzul™ has Begun

Sep 07, 2016

OTC Disclosure & News Service

Hancock, MD, Sept. 07, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, has commenced its pre-INAD (Investigational New Animal Drug) studies of Vitalzul^TMwith the inception of a cell lines study to identify the appropriate targets for safety and efficacy testing. In conjunction with InnoVision Therapeutics, the study will verify cancer cell types that have already been determined to be responsive to Vitazul^TMand determine the most appropriate target indication for clinical trials once initial safety and dosing studies are completed.

Cell lines studies are well accepted as one of the initial steps in drug development and testing ^1,2. Standard cancer cell lines are prepared and exposed to Vitalzul^TM. The amount of cell death can be measured by laboratory assay methods. The cell types identified as most susceptible to Vitalzul^TM will be ranked in order of appropriateness for further studies based not only on the cell lines study, but also their prevalence and known response to conventional therapy.

With this information, along with other studies to be announced shortly, the company anticipates scheduling a formal meeting with the FDA/CVM followed by application filing to the agency for approval of its clinical trial protocols.

Dr. Ramana, PetLife Pharmaceutical’s Chief Medical Officer, noted “These studies will put PetLife Pharmaceuticals on a direct path towards providing strong evidence-based research to the FDA, demonstrating the efficacy of Vitazul^TMin the treatment of cancer in our companion animals. The experience of InnoVision Therapeutics with the human formulation “Escozine” provides an added level of confidence to our efforts.”

CEO of PetLife Pharmaceuticals, Dr. Salvagno, commented “We are committed to moving this program forward in an expedited manner. Our recent capital raise is providing the funds to ensure that this process continues forward without interruption and with the full support of the entire PetLife team.”

Petlife’s 506 Private Placement Memorandum is available only to accredited investors.

References:

1)Daniela Ferreira, Filomena Adega and Raquel Chaves (2013). The Importance of Cancer Cell Lines as in vitro Models in Cancer Methylome Analysis and Anticancer Drugs Testing, Oncogenomics and Cancer Proteomics - Novel Approaches in Biomarkers Discovery and Therapeutic Targets in Cancer, Dr. Cesar Lopez (Ed.), InTech, DOI: 10.5772/53110. Available from: http://www.intechopen.com/books/oncogenomics-and-cancer-proteomics-novel-approaches-in-biomarkers-discovery-and-therapeutic-targets-in-cancer/the-importance-of-cancer-cell-lines-as-in-vitro-models-cancer-methylome-analysis-and-anticancer-d

2)Wilding JL, Bodmer, WF. Cancer Cell Lines for Drug Discovery and Development. Cancer Res 2014:74(9):2377-84

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife's mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology -- with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company's business prospects and performance. The Company's actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company's filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.28 29 ex99-28.htm

PetLife Pharmaceuticals Sees Vitalzul™ as a Major Component in the Treatment of Cancer in Pets; Releases Vitalzul™ Information and Testimonial Video

Sep 01, 2016

OTC Disclosure & News Service

Hancock, MD, Sept. 01, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, continues following the roadmap for FDA submission of Vitalzul™, a proposed cancer treatment for cats and dogs that has shown significant preliminary success in the reduction of tumors size as well as extension and quality of life of pets.

The American Veterinary Medical Association (AVMA) statistics indicate a 1 in 4 chance of dogs getting cancer, this rate increases to nearly 1 in 2 for dogs over 10 years old. Expenses in diagnosis and treatment grow quickly with biopsies of tissue, CT scans, MRI’s, etc. Once a diagnosis has been completed, the conventional options for treatment include: surgery, chemotherapy, radiation, cryosurgery (freezing), hyperthermia (heating) or immunotherapy. The average cost to treat lymphoma in pets is estimated to be $4,000. In late stage cases or depending on the type of cancer, euthanasia may be the only conventional option.

PetLife Pharmaceuticals’ Vitalzul™ is non-invasive and significantly less expensive than conventional treatments. This revolutionary new drug, with demonstrated ability to reduce tumor size and virtually no signs of toxicity or complications observed during clinical use, is made from Blue Scorpion venom extract. This drug is already approved in several countries as an oncology drug for humans, known as Escozine. PetLife Pharmaceuticals, working closely with InnoVision Therapeutics, is preparing the requisite paperwork for FDA submission and clinical trials.

Dr. Salvagno, CEO of PetLife Pharmaceuticals, has put together an eye-opening video explaining Vitalzul™ which he presents along with VP of Veterinary Affairs, Dr. Mitchell: https://www.youtube.com/watch?v=_yqZ1Gbm4hw

“We at PetLife Pharmaceuticals are very excited about the potential of Vitalzul™. Nearly 13 Million* pets receive a cancer diagnosis each year. Through our continued research we expect to show that our treatment will significantly extend the life expectancy of the pet population while keeping pet owner costs reasonable.” Dr. Salvagno, CEO of PetLife Pharmaceuticals, commented.

Petlife’s 506 Private Placement Memorandum is available only to accredited investors.

*Animal Cancer Foundation: http://www.acfoundation.org/faqs/

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology -- with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801

EX-99.29 30 ex99-29.htm

PetLife Pharmaceuticals Hires InnoVision Therapeutics in Preparation of Vitalzul™ FDA Submission

Aug 25, 2016

OTC Disclosure & News Service

HANCOCK, Md., Aug. 25, 2016 (GLOBE NEWSWIRE) — PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to announce the signing of a contract with InnoVision Therapeutics, a major step towards the Center for Veterinary Medicine (CVM)/FDA testing and approval process for Vitalzul™.

PetLife, having already made a deposit with InnoVision, will immediately begin pre-INAD studies (Investigational New Animal Drug) of Vitalzul™ with InnoVision Therapeutics.

InnoVision will work with the company to set up an initial meeting with the CVM to present and refine the regulatory pathway. Experts estimate that it will take between 18-24 months to complete the necessary pre-clinical and clinical studies needed for final FDA review.

Vitalzul™ is a new pet oncological treatment, based on Escozine, a blue scorpion venom treatment, which has been used for years to treat humans with cancer in many countries with no signs of toxicity or complications during clinical use. With its ease of administering and significantly lower cost than traditional treatments, PetLife is excited about its new Vitalzul™ product line and expects strong market acceptance.

“We are pleased to be working with PetLife Pharmaceuticals. Our great success with Escozine as a therapeutic drug in Humans will be of great benefit to PetLife’s Vitalzul™ CVM/FDA process,” stated Dr. Mishra, Managing Director of InnoVision Therapeutics.

Dr. Salvagno, CEO of PetLife Pharmaceuticals, comments on the company’s progress “We are delighted that InnoVision is taking PetLife on as a new client. Navigating the CVM/FDA waters is challenging and InnoVision’s experience will facilitate smooth travels. Moving our process forward opens up a new frontier in the ongoing oncological battle in pets, providing for less expensive and more effective treatment methods.”

Petlife Pharmaceuticals will be presenting Vitalzul™ at the San Francisco Money Show: August 23-25, 2016.

Petlife’s 506 Private Placement Memorandum is available only to accredited investors.

About InnoVision Therapeutics

InnoVision Therapeutics recognizes the vast potential of early stage Drug discovery and biological research, but realizes that it is only with the careful design and implementation of a sound development plan will this potential be realized. InnoVision Therapeutics experienced management team, Scientific Advisory Board and Board of Directors, apply a complex and rigorous screening process in order to determine which projects will be accepted. Once a project is accepted InnoVision Therapeutics designs a comprehensive drug development plan and assumes full responsibility for its progress and success. Throughout the process, InnoVision Therapeutics strives to maintain strong involvement of the inventors, companies and universities as partners in the drug development program. InnoVision Therapeutics is continuously seeking new therapeutic projects for a wide array of indications by partnering with innovative researchers and pharmaceutical companies to further develop their compounds to maximize the opportunity to create effective and marketable therapies.

For more information about InnoVision Therapeutics, please visit their website: http://www.innovision-pharma.com/

About Center for Veterinary Medicine (CVM)

The Center for Veterinary Medicine protects public and animal health by ensuring that animal drugs and medicated feeds are safe and effective and that food from treated animals is safe to eat. The responsibilities of CVM have a direct effect on the safety of the human food supply and on the safety to animals that are treated with veterinary products.

CVM regulates drugs, devices, and food additives for over 100 million companion animals, plus millions of poultry, cattle, swine, and minor animal species. (Minor animal species include animals other than cattle, swine, chickens, turkeys, horses, dogs, and cats.) For additional information, please visit: http://www.fda.gov/aboutfda/centersoffices/officeoffoods/cvm/default.htm

About PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals (OTCQB:PTLF) (http://www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication to the world of veterinary oncology — with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.

Safe Harbor

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.

Investor Relations:

Invicto Group

info@invictogroup.com

800-928-7462 Ext. 801